Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583422 · ClinicalTrials.gov registry record
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 16
- Enrollment target
NCT05583422 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT05583422 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results. Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy. Retrospective collection of treatment related AEs and SAEs, dose delays, dose reductions, and treatment discontinuations will be completed.
Interventions
- GENETIC DPYD or UGT1A1 variants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2024-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05583422
The ClinicalTrials.gov registry entry for NCT05583422 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DPYD or UGT1A1 variants is the first listed.
NCT05583422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05583422 about?
NCT05583422 is a clinical study titled "Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy". This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results. Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy. Retrospective collection of treatment related AEs and SAEs, dose...
What is the current status of trial NCT05583422?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2023-08-18. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT05583422?
The interventions under investigation include: DPYD or UGT1A1 variants (GENETIC).
Who is sponsoring clinical trial NCT05583422?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.